[go: up one dir, main page]

WO2021248254A3 - Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases - Google Patents

Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases Download PDF

Info

Publication number
WO2021248254A3
WO2021248254A3 PCT/CA2021/051414 CA2021051414W WO2021248254A3 WO 2021248254 A3 WO2021248254 A3 WO 2021248254A3 CA 2021051414 W CA2021051414 W CA 2021051414W WO 2021248254 A3 WO2021248254 A3 WO 2021248254A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacotherapeutic
hesperidin
doses
inflammatory mediators
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2021/051414
Other languages
French (fr)
Other versions
WO2021248254A2 (en
Inventor
Martin Robitaille
Pierre Laurin
Lyne Gagnon
Frank CESARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ingenew Pharma Inc
Original Assignee
Ingenew Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenew Pharma Inc filed Critical Ingenew Pharma Inc
Publication of WO2021248254A2 publication Critical patent/WO2021248254A2/en
Publication of WO2021248254A3 publication Critical patent/WO2021248254A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to multiple pharmacotherapeutic doses of hesperidin or related bioflavonoids for the prevention of viral entry and replication during infection(s) and/or to modulate inflammatory mediators reducing the potential for cytokine storm and organ injuries independent of disease etiology. More particularly, the invention relates to a formulation to prevent viral entry and replication during infection, comprising a flavonoid class compound in a therapeutically effective dose for human patients. There is also provided a method for modulation of inflammatory mediators inflammation post infection and a method for modulation of inflammatory mediators in acute or chronic inflammation related to an infection or a non-infectious disease etiology.
PCT/CA2021/051414 2020-10-09 2021-10-07 Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases Ceased WO2021248254A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089766P 2020-10-09 2020-10-09
US63/089,766 2020-10-09

Publications (2)

Publication Number Publication Date
WO2021248254A2 WO2021248254A2 (en) 2021-12-16
WO2021248254A3 true WO2021248254A3 (en) 2022-03-10

Family

ID=78846972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2021/051414 Ceased WO2021248254A2 (en) 2020-10-09 2021-10-07 Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases

Country Status (1)

Country Link
WO (1) WO2021248254A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7778495B2 (en) * 2021-07-02 2025-12-02 東洋精糖株式会社 Inhibitors of viral cell entry
CN115990179A (en) * 2022-12-16 2023-04-21 中山大学 Application of hesperidin in preparation of medicine for treating chronic obstructive pulmonary disease
CN116440121A (en) * 2023-06-02 2023-07-18 深圳市第二人民医院(深圳市转化医学研究院) Application of Diosmetin in preparation of medicine for treating non-alcoholic fatty liver disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998937B2 (en) * 2005-12-13 2011-08-16 Korea Research Institute Of Bioscience And Biotechnology Flavonoid compound having an antiviral activity
US20190365703A1 (en) * 2015-02-13 2019-12-05 Global Biolife Inc. Method and composition for preventing and treating viral infections
CN111773282A (en) * 2020-06-09 2020-10-16 广东金骏康生物技术有限公司 Medicine and food dual purpose Chinese medicinal preparation and its application
CN112546038A (en) * 2020-11-19 2021-03-26 澳门科技大学 Application of myricetin in preparation of medicine for preventing or treating coronavirus and influenza virus
WO2021194436A1 (en) * 2020-03-26 2021-09-30 Nanobiomed Sağlik Ve Yaşam Bilimleri A. Ş. The natural antiviral and anti-inflammatory compound consist of bioflavonoids which extracted from papaver rhoeas red petals
US20210299085A1 (en) * 2020-03-30 2021-09-30 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998937B2 (en) * 2005-12-13 2011-08-16 Korea Research Institute Of Bioscience And Biotechnology Flavonoid compound having an antiviral activity
US20190365703A1 (en) * 2015-02-13 2019-12-05 Global Biolife Inc. Method and composition for preventing and treating viral infections
WO2021194436A1 (en) * 2020-03-26 2021-09-30 Nanobiomed Sağlik Ve Yaşam Bilimleri A. Ş. The natural antiviral and anti-inflammatory compound consist of bioflavonoids which extracted from papaver rhoeas red petals
US20210299085A1 (en) * 2020-03-30 2021-09-30 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN111773282A (en) * 2020-06-09 2020-10-16 广东金骏康生物技术有限公司 Medicine and food dual purpose Chinese medicinal preparation and its application
CN112546038A (en) * 2020-11-19 2021-03-26 澳门科技大学 Application of myricetin in preparation of medicine for preventing or treating coronavirus and influenza virus

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Hesperidin and Diosmin for Treatment of COVID-19", CLINICALTRIALS.GOV NCT04452799, 30 June 2020 (2020-06-30), XP055915420, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/studv/NCT04452799> *
BARRECA DAVIDE, GIUSEPPE GATTUSO, ERSILIA BELLOCCO, ANTONELLA CALDERARO, DOMENICO TROMBETTA, ANTONELLA SMERIGLIO, GIUSEPPINA LAGAN: "Flavanones: Citrus phytochemical with health‐promoting properties", BIOFACTORS, vol. 43, no. 4, 12 May 2017 (2017-05-12), pages 495 - 506, XP055882394, DOI: 10.1002/biof.1363 *
BELLAVITE PAOLO, DONZELLI ALBERTO: "Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits", ANTIOXIDANTS, vol. 9, no. 8, 13 August 2020 (2020-08-13), pages 742, XP055915422, DOI: 10.3390/antiox9080742 *
HAGGAG ET AL.: "Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?", MEDICAL HYPOTHESES, vol. 144, no. 109957, 6 June 2020 (2020-06-06), pages 3, XP086361032, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.sov/pmc/articles/PMC7274964/pdf7main.pdf> DOI: 10.1016/j.mehy.2020.109957 [ISSN: 0306-9877 (Print)/ 1532-2777 (Electronic *
KAUL T N, MIDDLETON E, OGRA P L: "ANTIVIRAL EFFECT OF FLAVONOIDS ON HUMAN VIRUSES", JOURNAL OF MEDICAL VIROLOGY, JOHN WILEY & SONS, INC., US, vol. 15, no. 01, 1 January 1985 (1985-01-01), US , pages 71 - 80, XP000990920, ISSN: 0146-6615, DOI: 10.1002/jmv.1890150110 *
KIM DONG-HYUN, KIM DONG-HYUN, SONG MI-JEONG, BAE EUN-AH, HAN MYUNG: "Inhibitory Effect of Herbal Medicines on Rotavirus Infectivity.", BIOLOGICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO., JP, vol. 23, no. 3, 1 January 2000 (2000-01-01), JP , pages 356 - 358, XP055915424, ISSN: 0918-6158, DOI: 10.1248/bpb.23.356 *
PAREDES A., ALZURU M.; MENDEZ J.; RODRIGUEZ-ORTEGA M.: "Anti-Sindbis Activity of Flavanones Hesperetin and Naringenin", BIOLOGICAL & PHARMACEUTICAL BULLETINN, vol. 26, no. 1, 1 January 2003 (2003-01-01), pages 108 - 109, XP055915426 *
REPON KUMER SAHA, TADANOBU TAKAHASHI, TAKASHI SUZUKI: "Glucosyl Hesperidin Prevents Influenza A Virus Replication in Vitro by Inhibition of Viral Sialidase", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 32, no. 7, 1 May 2009 (2009-05-01), XP055395912, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/article/bpb/32/7/32_7_1188/_pdf> [retrieved on 20170803], DOI: 10.1248/bpb.32.1188 *
UTOMO ROHMAD YUDI, IKAWATI MUTHI', MEIYANTO EDY: "Revealing the Potency of Citrus and Galangal Constituents to Halt SARS-CoV-2 Infection", PREPRINTS, 11 March 2020 (2020-03-11), XP055852783, Retrieved from the Internet <URL:https://www.preprints.org/manuscript/202003.0214/v1> [retrieved on 20211019], DOI: 10.20944/preprints202003.0214.v1 *

Also Published As

Publication number Publication date
WO2021248254A2 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
WO2021248254A3 (en) Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases
Theoharides et al. Dexamethasone for COVID-19? Not so fast
Massarella et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64–0796/GS4104) in healthy adult and elderly volunteers
NO20051987L (en) Treatment of fungal infections.
MX2024012104A (en) Respiratory Stimulating Nasal Formulations
BR112021025764A2 (en) Pyrimidine derivative that inhibits the growth of cancer cells and medicinal use thereof
Farrior Histopathologic considerations in treatment of the eustachian tube
MX2021010834A (en) Compound and method for the prevention of transmission of influenza virus.
WO2022150719A3 (en) Antigenic composition(s) and method(s) against porphyromonas gingivalis for the prevention and/or treatment of infection and/or diseases
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
Regidor Covid-19 management with inflammation resolving mediators? Perspectives and potential
CL2022002832A1 (en) Inactivated vaccine for sars-cov-2 and preparation thereof
WO2020170035A3 (en) Method for treatment of rosacea including patient reported outcomes thereof
MX2022013722A (en) Cysteamine for the treatment of sars-cov-2 infection.
US11724077B2 (en) Therapeutic swabs for treating upper respiratory infections
JP7465587B2 (en) Compositions for the management of COVID-19 and related diseases
ZA202305383B (en) Topical administration of 2- (diethylamino) ethyl 2- (4-isobutylphenyl) propionate for treatment of diseases
Renzo et al. Short ribosomal prophylaxis in the prevention of clinical recurrences of chronic otitis media in children
NO20055512L (en) Therapy or prevention of respiratory viral infections with alpha-thymosin peptides
WO2023114356A3 (en) Spray dried inhalable biotherapeutics for the treatment of disease
MX2023005663A (en) RESPIRATORY TREATMENTS.
KR20060054190A (en) Agents to Inactivate Corona Virus
Bhuyan et al. Oral manifestations, pathogenesis and drug modalities in individuals infected with SARS-CoV-2
Taori et al. Pharmacological management of oral lesion
UA144734U (en) METHOD OF TREATMENT OF VIRAL INFECTIOUS DISEASES

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21821169

Country of ref document: EP

Kind code of ref document: A2